Medline (MDLN) Earnings Analysis
Medline (MDLN) has no confirmed upcoming earnings date. Last quarter (2026-02-25) it missed with EPS 0.22 USD vs 0.2381 USD est (-7.6%). It has beaten estimates in 0/1 recent quarters (0%). Trailing P/E 30.73.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does MDLN next report earnings?
No confirmed upcoming earnings date is currently scheduled for MDLN. This page updates as the calendar is published.
MDLN earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-25 | 0.22 USD | 0.2381 USD | -7.6% | Miss |
Beat rate: 0/1 (0%) over reported quarters with consensus data.
MDLN valuation and analyst view
| Trailing P/E | 30.73 |
|---|---|
| Trailing EPS | 1.177 USD |
| Price / book | 2.70 |
| Dividend yield | 0.00% |
| Market cap | 31.85B |
| Analyst consensus | Buy (12 buy / 2 hold / 0 sell) |
| Avg price target | 44 USD |
Related research pages
Frequently asked questions
When is Medline (MDLN)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for MDLN. This page updates as the calendar is published.
Did MDLN beat earnings last quarter?
In its 2026-02-25 report, MDLN posted EPS of 0.22 USD versus a 0.2381 USD estimate — a miss of 7.6%.
What is MDLN's earnings track record?
Over the last 1 reported quarters with consensus data, MDLN beat estimates 0 times (0%).
What is MDLN's current P/E ratio and EPS?
MDLN trades at a trailing P/E of 30.73 on trailing EPS of 1.177045177045177 USD.
What do analysts rate MDLN?
Analyst consensus is "Buy" across 14 ratings (0 strong buy, 12 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 44 USD.